Welcome to our dedicated page for PRF Technologies news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies stock.
PRF Technologies Ltd. reports developments across clinical-stage specialty pharmaceuticals and AI-driven solar analytics. The company focuses on reformulating established therapeutics for post-operative pain management and, through majority-owned LayerBio, is developing OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation.
PRF news also covers the company’s DeepSolar business unit, which develops AI-driven digital asset management, forecasting, performance monitoring, and technical due diligence tools for utility-scale solar plants. Recurring updates include ocular drug-delivery regulatory milestones, preclinical and clinical safety data, patent activity, SaaS deployments, commercial collaborations, capital actions, and governance changes.
PainReform Ltd. (NasdaqCM:PRFX) announced the appointment of Lotus Clinical Research as its CRO for the upcoming Phase 3 trial of PRF-110. This trial will focus on patients undergoing bunionectomy and hernia repair operations. LCR is specialized in analgesic studies, with a history of approximately 350 trials resulting in over ten approvals. Previous Phase 2 results showed PRF-110 provided pain relief for up to 72 hours, outperforming ropivacaine's 2-6 hours. The CEO stated confidence in the trial's design, aiming to address the opioid crisis while demonstrating safer pain relief options.
PainReform Ltd. (NASDAQ:PRFX) has appointed Ilan Hadar as its new CEO, effective immediately. With over 20 years in the pharmaceutical sector, Hadar has led operations and developed products in the U.S. and Israel. His previous roles include serving as Country Manager and CFO at Foamix Pharmaceuticals and Finance Director at Pfizer. The appointment comes as PainReform prepares for pivotal Phase 3 trials for its lead product PRF-110, aimed at changing post-operative pain management by reducing reliance on opioids.
PainReform Ltd. (NASDAQ:PRFX) has appointed Dr. Ellen Baron to its Board of Directors, enhancing its leadership after a recent IPO. Dr. Baron brings over 20 years of experience in the healthcare and capital markets sectors, previously holding key positions at Outcome Capital LLC and Healthios Capital Markets. Her expertise in business development and clinical affairs will be pivotal as PainReform advances its PRF-110 drug through Phase 3 trials aimed at the post-operative pain relief market. The company is optimistic about its future growth potential, targeting a significant market opportunity.
PainReform Ltd. (NASDAQ:PRFX) has appointed Augustine Lawlor to its Board of Directors following its recent IPO. Lawlor, with extensive experience in the pharmaceutical sector, previously served as COO of Leap Therapeutics and held key positions at LeukoSite and Alpha-Beta Technologies. His expertise includes finance, business development, and mergers and acquisitions, making him a valuable addition as PainReform advances its lead product, PRF-110, through Phase 3 trials. This product aims to revolutionize post-operative pain management while potentially reducing reliance on opioids.
PainReform Ltd. (NASDAQCM:PRFX) provided updates on its lead drug candidate PRF-110, demonstrating unique surgical benefits beyond pain relief. Studies showed PRF-110 does not affect suture integrity or wound healing, targeting the post-operative pain market. The drug offers up to 72 hours of pain reduction with no serious adverse events reported. As PainReform advances into Phase 3 studies for bunionectomy and hernia repair, the company believes PRF-110 could significantly alter post-surgical practices and address the opioid crisis, potentially capturing a share in the $12 billion market.
PainReform Ltd. (NASDAQ:PRFX) has initiated preparations for pivotal Phase 3 clinical trials of PRF-110, aimed at treating post-operative pain, following a successful initial public offering that raised $20 million. The FDA has granted an IND for PRF-110, supported by positive Phase 2 results. The trials are designed to be brief, with primary endpoints based on a standard pain scale. PRF-110, a clear, viscous solution containing the well-known anesthetic ropivacaine, is intended to provide localized and extended pain relief, potentially reducing opiate use. The post-operative pain market is projected to grow from $12 billion to over $45 billion by 2026.
PainReform Ltd. (NASDAQ:PRFX) closed its initial public offering on September 3, 2020, offering 2,500,000 units at $8.00 each, yielding approximately $20 million before expenses. Each unit comprises one Ordinary Share and one Warrant for an additional share, separable upon issuance. The Ordinary Shares began trading on Nasdaq on September 1, 2020. Underwriters have a 45-day option to purchase up to 375,000 additional shares or warrants to cover over-allotments. PainReform focuses on reformulating established therapeutics, with its lead product PRF-110 targeting post-operative pain relief.
PainReform Ltd. (NasdaqCM:PRFX) has announced the pricing of its initial public offering (IPO) involving 2,500,000 units at $8.00 per unit. Each unit includes one Ordinary Share and one Warrant. The offering aims to raise approximately $20.0 million in gross proceeds, and it is expected to close on September 3, 2020. The Company’s shares will start trading on the Nasdaq Capital Market under the symbol PRFX on September 1, 2020. The Company has provided an option for underwriters to purchase an additional 375,000 shares.